DOI:
10.1055/s-00000009
American Journal of Perinatology
LinksClose Window
References
Lanctôt KL, Masoud ST, Paes BA. , et al.
The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
Curr Med Res Opin 2008;
24 (11) 3223-3237
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.